Amniotic Fluid Lactate in Perterm Premature Rupture of Membranes

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Rupture of Membranes; Premature Clinical Trial

Official title:
Amniotic Fluid Lactate in Predicting Latency in Perterm Premature Rupture of Membranes

Status Recruiting

Clinical Trial Summary

AF lactate level could help in predicting the duration from ROM till delivery

n/a

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05958953` - PeRinatal Outcomes With ACTive Versus Expectant Management of Women With Pre-labor Rupture Of Membranes	Phase 3
Completed	`NCT03838965` - The Effects of Labor Stages and Interventions on Hemodynamic Measures During & After Childbirth With Noninvasive Sensors	N/A
Recruiting	`NCT04632017` - Computerized Cardiotocography Monitoring of Fetuses With pPROM
Recruiting	`NCT03213535` - Urea and Creatinine Level in Vaginal Fluid as a Predicator for Length of Latency Period in Prelabour Membranes Rupture	N/A
Recruiting	`NCT04047849` - Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA	Phase 4